Canada: New Rules For Marketing Health Products To Consumers In 2017 – Get Ready To Preclear Canadian Advertising For Medical Devices And Vaccines

Last Updated: January 3 2017
Article by Jennifer McKenzie, Catherine Lovrics and Tony Orsi

Since 1997, Advertising Standards Canada (ASC) has been responsible for preclearing consumer directed advertising of non-prescription drugs. Since then, ASC's jurisdiction has expanded to include consumer directed advertising of natural health products and communications regarding prescription drugs (i.e. both "information" pieces and limited name brand "advertising").

Consumer directed advertising of medical devices and vaccines has previously been outside ASC's jurisdiction, leaving an anomalous gap in advertising oversight. This is about to change. On November 22, 2016, ASC closed its consultation on an update to the 2006 Consumer Advertising Guidelines for Marketed Health Products (the "New Guidelines"). The decade of living with the old guidelines informed the improvements that needed to be made. The New Guidelines are more streamlined and user friendly, and substantively, they fill some voids that have existed over the last 10 years and beyond.   

Formal preclearance for consumer directed advertising of medical devices and vaccines is expected to begin in early 2017, and an advisory opinion (which has always been available) can be sought now.

(a) Medical Device Advertising Review

As of 2014, medical devices were an estimated $6.7 billion industry in Canada. Medical devices are pervasive in our lives. From toothbrushes, condoms and tampons to pregnancy tests and blood glucose monitors, we interact with them every day. They are regulated by Health Canada. There are four classes of medical devices with Class I being the least invasive (e.g. manual toothbrush, thermometers, bandages) to Class IV being the most invasive (e.g. breast implants). Classes II to IV medical devices require licenses to be sold in Canada, whereas Class 1 medical devices do not.  

Advertising of medical devices is regulated, but to date, there has been no preclearance required for such advertising. For example, the Food and Drugs Act ("FDA") prohibits anyone from advertising a medical device in a way that is false, misleading, deceptive or likely to create an erroneous impression concerning its merit or safety, among other things. Furthermore, manufacturers are only permitted to make those claims found in the license or market authorization granted by Health Canada. 

ASC currently reviews the advertising of non-prescription drugs and natural health products directed to consumers. However, medical devices were not part of ASC's jurisdiction, nor was any other agency tasked with regular review of consumer directed advertising of medical devices. This gap was strange since medical devices are very much like non-prescription drugs and natural health products in that we use them for similar purposes, such as the diagnosis and treatment of diseases, and correcting or modifying certain functions of the body. The New Guidelines close this gap. (As an aside, the Pharmaceutical Advertising Advisory Board preclears advertising directed to healthcare professionals and medical devices and vaccines have long been within their jurisdiction, making this previous gap in consumer directed advertising for these categories even stranger.)

The focus of ASC's preclearance will be on communicating benefits and risks, in accordance with the market authorization granted by Health Canada. ASC will preclear advertising for Class II to IV medical devices. It is anticipated that ASC preclearance will have its largest effect on Class II medical devices. Class I medical devices will not require preclearance since Class I medical devices do not require a license to be sold, and generally do not carry a commensurate level of risk to warrant heavy regulatory oversight.

(b) Vaccines

For context, direct-to-consumer-advertising ("DTCA") of prescription drugs is a controversial subject. In most countries it is permitted to some extent. However, in Canada, there is a general prohibition on DTCA of prescription drugs (i.e. those listed on Schedule F of the FDA). There is a limited exception: you can advertise the name (brand and chemical), price and quantity of a Schedule F drug directly to consumers. Any express or implied claims regarding the named drug's therapeutic indication are strictly prohibited. In the late 1990s, Canadians started to see the proliferation of ads such as "VIAGRA. TALK TO YOUR DOCTOR". These "brand name" or "reminder" ads are "legal" provided they contain no express or implied representations (including innuendo and visual cues) regarding the therapeutic indication of the named drug. 

Vaccines are not listed on Schedule F; rather they are listed on Schedule D and because the section of the Food and Drug Regulations prohibiting DTCA refers specifically to Schedule F drugs, vaccines were seemingly not subject to the same prohibition as drugs. Consequently, Canadians started to see brand name advertising for vaccines that identified the therapeutic indication such as immunity from hepatitis A and B. More recently, ads for vaccines for HPV were controversial since they targeted sexually active teenagers. Vaccine ads seemed strange in the Canadian landscape, due to the general prohibition of DTCA and the limited exception for name brand advertising that was permitted. 

To try to address the anomaly, at least on an interim basis, Health Canada issued a document called "Interim Guidance: Fair Balance in Direct-to-Consumer Advertising" ("Interim Guidance"). The Interim Guidance recommended fair balance in vaccine advertising. For example, the document stated that advertising should not only discuss the positive benefits of vaccines but also include information about the most common and serious side effects, allergic reactions, precautions and warnings, contraindications in certain populations, as well as information related to the protection offered by the vaccine (duration, need for boosters, etc.). While Health Canada also encouraged vaccine manufacturers to submit advertising to ASC prior to dissemination, this was not a requirement. However, with the New Guidelines, review of vaccine advertising by ASC becomes more than a recommendation. The New Guidelines also supplement the Interim Guidance by providing examples of how to communicate risk in advertising for flu, HPV and travel vaccines. For example, regarding the HPV vaccine, example language reads: "Product X helps protect girls/women against cervical cancer caused by HPV (type #). It does not protect against all HPV strains and may not protect everyone who is vaccinated. Regular Pap tests should continue after vaccination. Side effects and allergic reactions can occur. Visit URL for more information".

(c) Some highlights from the New Guidelines

The New Guidelines are concise and follow ASC's other guidelines by providing numerous examples in each category of acceptable and unacceptable advertising claims. Some highlights of the New Guidelines now follow:

GENERAL CONSIDERATIONS

  • To assess compliance with the New Guidelines, advertising will be considered as a whole, including visuals.  
  • Ads must present fair, balanced and accurate information about both the benefits and risks of the product. 
  • Paraphrasing consistent with the market authorization is permitted, unless the authorization prescribes language.  
  • There are specific technical requirements for the duration, contrast, placement, volume and/or font of supers used in video, audio and print, out of home and online advertising.

RECOMMENDED USE

  • Advertising must clearly communicate the product's indication and recommended use according to the market authorization issued by Health Canada (namely, indications for use for Class II medical devices, authorized labelling for Class III and IV medical devices, and the product monograph for vaccines).  
  • Directions for use, duration of use and storage need not be described in the advertising, but if described, must be consistent with the market authorization.

NEW CLAIM ABOUT AUTHORIZED SALE

  • The claim "Product X is authorized for sale by Health Canada" is permitted for all drugs, NHPs and medical devices (except Class I) since they must all be reviewed and approved by Health Canada prior to sale. However, the advertisement must not otherwise imply endorsement, approval or recommendation by Health Canada or another government agency

CLAIMS OF HEALTH BENEFITS AND COMPOSITION

  • Advertising can promote health benefits in accordance with the market authorization for the advertised product.
  • Claims exceeding the market authorization, including health promotion claims, may be permitted if they are true and substantiated, and the advertiser should expect to provide evidence that the claim was authorized by Health Canada. 

Non-therapeutic claims may also be made, provided they do not imply a therapeutic benefit or obscure the therapeutic indication.

  • "Organic" claims are permitted for ingredients and products if certified according to recognized standards, with evidence of certification being required upon request. "Natural" claims are permitted for products and ingredients, provided Health Canada definitions are met.

DESCRIPTION OF RISKS

  • Known risks must be communicated, but it may not be necessary to detail risks in the advertising. The New Guidelines permit directing the consumer to the label (e.g. "This product may not be right for you. Always read and follow the label"), and a website for additional risk information if the label is not up-to-date (e.g. "For more information visit ...").  
  • The New Guidelines are prescriptive about risk disclosures in advertising for different product categories, including medical devices. For example, for medical devices where injuries/infections can happen or improper use may worsen a condition, the consumer must also be advised that the product may not be suitable for everyone, may not be used under certain circumstances, and it must be explained that the product has to be used/handled with caution.  Specific examples of acceptable language are provided in the New Guidelines.

CLAIMS REGARDING PERFORMANCE

  • The basis for comparative claims against prior models, competitive products, and non-medical devices must be clearly communicated.  
  • There will remain a one year clock on "new", "improved", and similar claims. 
  • Ads must not to exaggerate product performance, imply a product is risk free, natural, or convey it is essential to use the product.  For example, words such as "amazing", "powerful", "fantastic" and "unique" are likely to present hurdles to clearance, and "guarantee" claims will not be permitted, nor will "safe", "side effect free", "no known side effects", and most "natural" claims.  
  • Testimonials, endorsements, seals of approval, and user generated content may be permitted, provided they are consistent with the market authorization for the product

INTENDED AUDIENCE

  • Advertising must be overtly directed to adults, and not suggest that a child is capable of making a rational decision regarding use of advertised health product.

While ASC has stated that the New Guidelines are consistent with international norms, there will no doubt be Canadian nuances. Generally, ASC works with advertisers to get advertising cleared. However, until there is a better understanding of how the New Guidelines will play out in practice, submitting advertising for pre-clearance sooner than later will leave more time for changes to be accommodated.  

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Jennifer McKenzie
Catherine Lovrics
Tony Orsi
Similar Articles
Relevancy Powered by MondaqAI
Global Advertising Lawyers Alliance (GALA)
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Global Advertising Lawyers Alliance (GALA)
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions